Tracked deals
9
9 tracked deals across 2015-2026.
Pharmaceuticals Buyers & Acquisitions in New York
Buyer mix
Mixed buyer set
8 pe · 5 strategic
Top trend
Volume peaked in 2026
2 tracked deals announced in 2026.
Primary Insight
What Stands Out
- Strategics and biotechs: Eli Lilly and Company targets oncology pipeline expansion (AJ1-11095) in Phase 1.
- Rights and commercialization: Axsome Therapeutics secured exclusive global rights to AZD7325 via an acquisition and amended license.
- Manufacturing + channel access: TopGum Industries Ltd. acquired U.S. gummy manufacturing operations and paired the deal with a long-term retailer commercialization arrangement.
- Category expansion in New York: Geritrex’ add-on acquisition emphasized liquid dosage manufacturing and private-label/exports.
- Investor-led platform growth: New York deals include platform and growth backing for OTC/veterinary pharmaceutical capabilities through RF Investment Partners, Aquimont Capital, Miramar Equity Partners, and others.
Build a buyer list for your Pharmaceuticals deal
Find buyers actively acquiring pharmaceuticals companies.
Find buyers like these for your dealBuyer Snapshot
Top Buyers
Illustrative buyers pulled from tracked transactions on this page. This table is capped and intentionally non-exhaustive.
| Buyer | # Deals | Focus | Type |
|---|---|---|---|
| Aquimont Capital | 1 | Healthcare-focused investment firm that partners with nic... | PE |
| Axsome Therapeutics | 1 | Public biopharmaceutical company developing novel therapi... | Strategic |
| BelHealth Investment Partners | 1 | Healthcare-focused private equity firm investing in lower... | PE |
| Biocodex Group | 1 | French pharmaceutical company focused on microbiota care,... | Strategic |
| Comvest Partners | 1 | Operationally focused middle-market private investment fi... | PE |
| Eli Lilly and Company | 1 | Global biopharmaceutical company with an oncology franchi... | Strategic |
| Geritrex | 1 | Manufacturer and distributor of topical generic OTC produ... | Strategic (PE-backed) |
| Leedon Park Capital LLC | 1 | Middle-market private equity firm focused on long-term pa... | PE |
| Miramar Equity Partners | 1 | Private equity platform of Miramar Holdings (a Dallas-bas... | Family Office |
| NewSpring Mezzanine | 1 | Middle-market private equity firm offering growth equity,... | PE |
Acquisition Volume in Pharmaceuticals in New York by Year
Last 5 years
Actual
Full-year estimate
Supporting Data
Recent Transactions
-
- Buyer
- TopGum Industries Ltd.
- Target
- P26L Developments LLC, P L Developments LLC, PL Developments LLC (PLD)
- Industry
- Pharmaceuticals
- Location
- New York, United States
- Type
- Buyout
TopGum Industries Ltd. completed the acquisition of the U.S. gummy manufacturing operations of P26L/PL Developments LLC (PLD). TopGum also entered a long-term commercial partnership with PLD under which PLD will commercialize and distribute TopGum-manufactured gummy products to leading U.S. retailers under store-brand labels.
-
April 27, 2026
- Buyer
- Eli Lilly and Company
- Target
- Ajax Therapeutics, Inc.
- Industry
- Pharmaceuticals
- Location
- New York, United States
- Type
- Buyout
Eli Lilly and Company announced a definitive agreement to acquire Ajax Therapeutics, Inc. in a deal valued at up to $2.3 billion, including upfront and milestone-based payments. The acquisition is intended to expand Lilly’s oncology pipeline with Ajax’s lead candidate, AJ1-11095, a Type II JAK2 inhibitor in Phase 1 development for myelofibrosis, including patients previously treated with Type I JAK2 inhibitors.
-
- Buyer
- Axsome Therapeutics
- Target
- Baergic Bio
- Seller
- Avenue Therapeutics, Baergic Bio shareholders
- Industry
- Pharmaceuticals
- Location
- New York, United States
- Type
- Buyout
Axsome Therapeutics acquired a 100% equity interest in Baergic Bio (a subsidiary of Avenue Therapeutics) and amended Baergic Bio's license with AstraZeneca to obtain exclusive global rights to AZD7325, an early‑stage selective GABAA α2,3 receptor modulator for epilepsy. The deal includes a $0.3 million upfront payment to Baergic Bio shareholders and potential development, regulatory, sales‑based milestones and tiered royalties to Avenue Therapeutics and AstraZeneca as described in the purchase and amended license agreements.
-
September 2, 2025
- Buyer
- PharmaCyte Biotech, Inc.
- Target
- TNF Pharmaceuticals, Inc.
- Industry
- Pharmaceuticals
- Location
- New York, United States
- Type
- Growth capital
PharmaCyte Biotech, Inc. increased its equity stake in TNF Pharmaceuticals, Inc. by $3.0 million to support TNF's recent license agreement with LightSolver for a light-based compute accelerator intended for cryptocurrency and blockchain applications. The investment is positioned to help TNF execute a strategic pivot tied to the new license; PharmaCyte said it remains well-capitalized and may pursue further portfolio opportunities.
-
September 19, 2024
- Buyer
- RF Investment Partners, Aquimont Capital, Miramar Equity Partners
- Target
- Altro Pharmaceuticals, Amici Pharmaceuticals
- Industry
- Pharmaceuticals
- Location
- New York, United States
- Type
- Growth capital
RF Investment Partners announced a platform investment in Long Island-based sister companies Altro and Amici Pharmaceuticals, partnering with Aquimont Capital and Miramar Equity Partners to support growth in the companion animal/veterinary pharmaceutical market. The investment provides flexible debt and equity capital to expand sourcing, manufacturing and distribution capabilities for generic pharmaceuticals that serve both veterinary and human end markets.
-
November 17, 2022
- Buyer
- Biocodex Group
- Target
- Hilma
- Industry
- Pharmaceuticals
- Location
- New York, United States
- Type
- Buyout
French pharmaceutical group Biocodex has acquired a majority stake in Hilma, a U.S.-based natural remedies start-up founded by Hilary Quartner, Nina Mullen and Lily Galef. The deal gives Biocodex a stronger foothold in the U.S. digestive-health and women’s-health segments and will help scale Hilma’s omnichannel retail strategy (DTC plus 750+ stores including Target).
-
September 7, 2022
- Buyer
- SK Capital Partners, Comvest Partners
- Target
- VanDeMark Chemical, Inc.
- Industry
- Pharmaceuticals
- Location
- New York, United States
- Type
- Growth capital
Funds advised by SK Capital Partners have made a strategic investment in VanDeMark Chemical, a Comvest Partners portfolio company headquartered in Lockport, New York. Comvest remains a co-owner; the investment will accelerate VanDeMark's growth and deepen its focus on life-science specialty chemistries, with SK Capital supporting organic and inorganic expansion.
-
April 27, 2021
- Buyer
- NewSpring Mezzanine (NewSpring Capital), Tecum Capital (Tecum Capital Partners), Leedon Park Capital LLC, PNC Bank (PNC Financial Services Group)
- Target
- Spirit Pharmaceuticals LLC
- Industry
- Pharmaceuticals
- Location
- New York, United States
- Type
- Growth capital
An investor group led by NewSpring Mezzanine, alongside Tecum Capital, Leedon Park Capital and PNC Bank provided a growth capital injection into Spirit Pharmaceuticals LLC, backing CEO and founder Ajoy Joshi. The funding will support the Long Island-based private-label developer, packager and distributor of over-the-counter pharmaceutical products as it expands capacity (two additional facilities, 11 packaging lines) and deepens relationships with big-box retailers, medical distributors and e-commerce customers.
-
November 9, 2015
- Buyer
- Geritrex, BelHealth Investment Partners
- Target
- PurinePharma
- Industry
- Pharmaceuticals
- Location
- New York, United States
- Type
- Addon
Geritrex, a BelHealth Investment Partners portfolio company, has acquired the business and assets of PurinePharma, a private-label manufacturer and distributor of OTC liquid nasal, allergy, and cough & cold products based in Massena, New York. The add-on expands Geritrex's manufacturing capabilities into liquid dosage forms, provides access to the retail private-label channel and export markets, and adds a CGMP-approved manufacturing facility in upstate New York.
Build a buyer list for your Pharmaceuticals deal
Find buyers actively acquiring pharmaceuticals companies.
Frequently Asked Questions
Which New York pharmaceuticals deals involve major strategics?
The listed New York-focused headlines include Eli Lilly and Company’s announced acquisition of Ajax Therapeutics, Inc. (oncology pipeline) and Axsome Therapeutics’ acquisition of Baergic Bio (exclusive global rights tied to AZD7325).
Do the New York transactions focus on R&D, commercialization, or both?
Both themes appear. Some deals are positioned to expand pipeline programs (e.g., AJ1-11095), while others emphasize commercial and manufacturing execution (e.g., gummy manufacturing with retailer store-brand distribution; scale-up of packaging and distribution for OTC products).
Which deals highlight manufacturing and private-label distribution?
TopGum Industries Ltd. completed an acquisition of U.S. gummy manufacturing operations and entered a long-term commercial partnership for store-brand distribution. Geritrex’ acquisition of PurinePharma similarly emphasized liquid dosage manufacturing plus retail private-label and export access.
Are there investor-backed transactions in New York pharmaceuticals?
Yes. Examples include investor groups backing growth at Spirit Pharmaceuticals LLC and a platform investment in Long Island-based sister companies Altro Pharmaceuticals and Amici Pharmaceuticals involving RF Investment Partners, Aquimont Capital, and Miramar Equity Partners.
Related Acquisition Pages
Pharmaceuticals Buyers & Acquisitions
Pharmaceuticals Buyers & Acquisitions in Canada
Private Equity-Backed Pharmaceuticals Buyers
Pharmaceuticals Acquisitions in 2026
Pharmaceuticals Acquisitions in 2025
Pharmaceuticals Acquisitions in 2024
Pharmaceuticals Acquisitions in 2022
Pharmaceuticals Acquisitions in 2021
Pharmaceuticals Acquisitions in 2015
Acquisitions in New York
Private Equity-Backed Acquisitions in New York
Acquisitions in New York in 2026